(This Feb 6. story has been corrected to show the damages are according to an expert report, and not estimated by IHH's unit.

IHH Healthcare said on Thursday its unit has sought up to 109.3 billion rupees ($1.25 billion) in compensation from Japan's ...

IHH’s subsidiary Northern TK Venture (NTK) had filed a claim against Daiichi Sankyo saying the latter prevented NTK from ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Northern TK Venture Pte Ltd, IHH Healthcare's Singaporean arm, has raised its claim against Daiichi Sankyo in Tokyo for ...

IHH Healthcare Bhd’s share price on Bursa Malaysia edged higher in early trading after its unit Northern TK Venture Pte Ltd ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

IHH Healthcare seeks ₹10,930 crore compensation from Daiichi Sankyo for Fortis Healthcare stake buy legal dispute.